US crackdown on Chinese biotech opens opportunities for Indian companies

The recent US crackdown on Chinese biotech companies marks a significant shift in the global biotechnology landscape, with profound implications for competitive strategies.

The move, driven by concerns over intellectual property theft, data privacy, and national security, has led to increased scrutiny and sanctions on Chinese biotech firms. This regulatory tightening is creating a vacuum in the biotech sector, presenting an opportunity for biotech companies from other countries, particularly India, to step in and fill the gap, reports The Pharma Letter’s India correspondent.

The BIOSECURE Act aligns with China's accelerated regulatory reforms, which streamline drug approvals and attract global companies and investors. However, geopolitical tensions have prompted global drug majors to reassess their dependence on Chinese suppliers.